[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1793
2. Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD: A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. J Thorac Oncol; 2016 Jun;11(6):838-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
  • INTRODUCTION: Serine/threonine kinase 11 gene (STK11), better known as liver kinase β1, is a tumor suppressor that is commonly mutated in lung adenocarcinoma (LUAD).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biological Assay / methods. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Mutation. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Cohort Studies. Humans. Nanotechnology. Neoplasm Staging. Prognosis. ROC Curve

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
  • [Cites] Nature. 2012 Mar 29;483(7391):613-7 [22425996.001]
  • [Cites] J Clin Oncol. 2010 Oct 10;28(29):4417-24 [20823422.001]
  • [Cites] J Natl Cancer Inst. 2015 Jan;107(1):358 [25465874.001]
  • [Cites] Oncogene. 2016 Jun 16;35(24):3209-16 [26477306.001]
  • [Cites] J Clin Oncol. 2011 Feb 20;29(6):e150-3 [21189378.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1616-25 [16953221.001]
  • [Cites] Oncotarget. 2015 Nov 25;:null [26625312.001]
  • [Cites] Biochem J. 2008 Nov 15;416(1):1-14 [18774945.001]
  • [Cites] Sci Transl Med. 2013 May 22;5(186):186ra66 [23698379.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Mar;137(3):580-6 [19258070.001]
  • [Cites] Ann Oncol. 2014 Feb;25(2):339-45 [24347518.001]
  • [Cites] J Thorac Oncol. 2010 Aug;5(8):1130-5 [20559149.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5911-8 [17384680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18892-7 [20956321.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Fam Cancer. 2011 Sep;10(3):447-53 [21516316.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):899-905 [20164920.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1283-92 [15800014.001]
  • [Cites] J Thorac Oncol. 2014 Jun;9(6):794-804 [24828662.001]
  • [Cites] Clin Cancer Res. 2015 Jun 15;21(12):2851-60 [25737507.001]
  • [Cites] Curr Biol. 2003 Nov 11;13(22):2004-8 [14614828.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Biotechnol. 2008 Mar;26(3):303-4 [18327243.001]
  • [Cites] Protein Cell. 2011 Feb;2(2):99-107 [21380642.001]
  • [Cites] Nature. 2014 Jul 31;511(7511):543-50 [25079552.001]
  • [Cites] Oncogene. 2015 Apr 30;34(18):2337-46 [24998845.001]
  • [Cites] Oncogene. 2011 Sep 1;30(35):3784-91 [21532627.001]
  • [Cites] Oncogene. 2000 Jan 6;19(1):164-8 [10644993.001]
  • [Cites] Oncogene. 2012 Jan 26;31(4):469-79 [21706049.001]
  • [Cites] Oncogene. 2010 Mar 18;29(11):1672-80 [20010869.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Clin Cancer Res. 2013 Jan 1;19(1):194-204 [23032747.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3562-5 [18483235.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):370-5 [19165201.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6365-75 [15561763.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] J Natl Cancer Inst. 2011 Dec 21;103(24):1859-70 [22157961.001]
  • [Cites] Cancer Cell. 2013 Feb 11;23(2):143-58 [23352126.001]
  • [Cites] Cancer Cell. 2015 May 11;27(5):698-711 [25936644.001]
  • [Cites] Cancer Res. 2015 Jul 1;75(13):2587-93 [26069246.001]
  • [Cites] Cancer Cell. 2010 Jun 15;17(6):547-59 [20541700.001]
  • [Cites] Oncogene. 2016 Feb 18;35(7):856-66 [26119936.001]
  • [Cites] Nature. 2012 Sep 27;489(7417):519-25 [22960745.001]
  • (PMID = 26917230.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091353; United States / NCI NIH HHS / CA / P30 CA076292; United States / NCI NIH HHS / CA / P50 CA119997; United States / NCI NIH HHS / CA / R01 CA090489
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS762584 [Available on 06/01/17]; NLM/ PMC4877210 [Available on 06/01/17]
  • [Keywords] NOTNLM ; COX-2 inhibition / LKB1 / NanoString / STK11 / biomarker
  •  go-up   go-down


3. Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC: Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer; 2016 04 26;16(5):305-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?
  • In parallel, there has been a dramatic rise in the incidence of oesophageal adenocarcinoma (OAC) in the lower oesophagus, which is associated with antecedent Barrett oesophagus (BO).
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Gastroenterology. 2015 Jun;148(7):1392-404.e21 [25725293.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Nat Genet. 2015 Sep;47(9):1038-46 [26192915.001]
  • [Cites] Gastrointest Endosc. 1996 Dec;44(6):700-5 [8979061.001]
  • [Cites] Gut. 2012 Dec;61(12):1678-85 [22198711.001]
  • [Cites] Dev Biol. 2012 Mar 15;363(2):426-37 [22285812.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] PLoS One. 2012;7(4):e35486 [22530031.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):489-511 [15668262.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Dev Biol. 2010 Mar 1;339(1):155-65 [20043902.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):915-20 [18536716.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):99 [11808612.001]
  • [Cites] Nature. 2015 Feb 19;518(7539):360-4 [25693567.001]
  • [Cites] Dev Cell. 2009 Apr;16(4):588-99 [19386267.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1395-408 [23697611.001]
  • [Cites] Dis Esophagus. 2010 Feb;23(2):168-74 [19549212.001]
  • [Cites] Dis Esophagus. 2006;19(4):260-6 [16866857.001]
  • [Cites] Aliment Pharmacol Ther. 2014 May;39(9):984-91 [24617286.001]
  • [Cites] Gut. 2013 Feb;62(2):192-200 [22362916.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Crit Rev Oncog. 2006 Jul;12(1-2):3-26 [17078204.001]
  • [Cites] J Clin Gastroenterol. 2013 Apr;47(4):322-7 [22914345.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17 ):6162-70 [16144916.001]
  • [Cites] Gut. 2014 Aug;63(8):1229-37 [24221456.001]
  • [Cites] Gut. 2014 Mar;63(3):385-94 [23729675.001]
  • [Cites] Gut. 2015 May;64(5):707-19 [25053715.001]
  • [Cites] PLoS One. 2013 Dec 10;8(12):e82390 [24340024.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1904-9 [11419427.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):915-9 [8088767.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7565-70 [15894614.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1523-30 [10228075.001]
  • [Cites] Cancer. 2003 Jun 15;97(12 Suppl):3133-275 [12784323.001]
  • [Cites] Gut. 2015 Apr;64(4):544-53 [24951258.001]
  • [Cites] Gut. 2010 Feb;59(2):156-63 [19651631.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):204-12 [16249283.001]
  • [Cites] Gut. 2012 Oct;61(10):1380-9 [22200839.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):689-96 [11875002.001]
  • [Cites] Nat Genet. 2013 Dec;45(12):1487-93 [24121790.001]
  • [Cites] Gut. 1999 Oct;45(4):489-94 [10486353.001]
  • [Cites] Cancer Cell. 2011 Feb 15;19(2):257-72 [21316604.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5438-42 [10554013.001]
  • [Cites] Nature. 2011 Sep 18;478(7368):255-9 [21927002.001]
  • [Cites] Gut. 2014 Dec;63(12 ):1854-63 [24550372.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Ann Thorac Surg. 2013 Dec;96(6):1927-32 [23987898.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):769-74 [12239615.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):309-13 [10495421.001]
  • [Cites] Sci Transl Med. 2014 Aug 20;6(250):250ra115 [25143365.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(16):2867-73 [19427197.001]
  • [Cites] Cancer Res. 2010 Nov 1;70(21):8435-45 [20959488.001]
  • [Cites] Cell. 2011 Jun 24;145(7):1023-35 [21703447.001]
  • [Cites] Gastroenterology. 2011 Feb;140(2):412-24 [21144849.001]
  • [Cites] J Exp Med. 2011 Apr 11;208(4):677-88 [21402740.001]
  • [Cites] Aliment Pharmacol Ther. 1993 Dec;7(6):623-8 [8161668.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Clin Invest. 2014 Mar;124(3):1283-95 [24487592.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 7;294(2):470-9 [12051735.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):666-73 [19382179.001]
  • [Cites] Nat Genet. 2012 May;44(5):570-4 [22484628.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Gastroenterology. 2016 Apr;150(4):918-30.e13 [26677984.001]
  • [Cites] Cancer Discov. 2012 Oct;2(10 ):899-905 [22877736.001]
  • [Cites] Cell Rep. 2013 Oct 31;5(2):349-56 [24209744.001]
  • [Cites] Nat Genet. 2013 May;45(5):478-86 [23525077.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Hum Mutat. 1999;13(2):171 [10094558.001]
  • [Cites] World J Gastroenterol. 2013 Apr 28;19(16):2560-8 [23674860.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Nat Commun. 2016 Jan 19;7:10380 [26783136.001]
  • [Cites] Ann N Y Acad Sci. 2011 Sep;1232:1-17 [21950804.001]
  • [Cites] Gastroenterology. 2012 Jun;142(7):1424-30 [22537611.001]
  • [Cites] Nature. 2013 Jul 11;499(7457):214-8 [23770567.001]
  • [Cites] J Pathol. 1994 Aug;173(4):317-26 [7965391.001]
  • [Cites] Gastroenterology. 2010 Jun;138(7):2207-10, 2210.e1 [20450866.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1039-45 [19904251.001]
  • [Cites] World J Surg. 2011 Mar;35(3):617-24 [21203759.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):899-905 [20164920.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):402-9 [10716154.001]
  • [Cites] Cell. 2013 Jan 17;152(1-2):25-38 [23273993.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Ann Surg. 2014 Dec;260(6):1023-9 [24836142.001]
  • [Cites] Carcinogenesis. 2013 Dec;34(12):2750-6 [23996928.001]
  • [Cites] Cancer Res. 2011 Dec 1;71(23):7187-97 [21990320.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Feb;12(2):239-45 [23988686.001]
  • [Cites] Science. 2010 Jan 29;327(5965):542-5 [20110496.001]
  • [Cites] Cell. 2013 Oct 10;155(2):357-68 [24120136.001]
  • [Cites] Br J Cancer. 2009 May 5;100(9):1503-7 [19352380.001]
  • [Cites] Nat Rev Clin Oncol. 2013 Nov;10(11):643-55 [24061039.001]
  • [Cites] Dev Cell. 2005 Apr;8(4):611-22 [15809042.001]
  • [Cites] Nat Genet. 2014 Jun;46(6):573-82 [24816253.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):478-86 [9247467.001]
  • [Cites] Anat Rec. 1993 Jun;236(2):259-79 [8338232.001]
  • [Cites] Cell. 2012 Mar 30;149(1):146-58 [22464327.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Scand J Gastroenterol. 2013 Jun;48(6):688-95 [23544442.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] ScientificWorldJournal. 2008 Nov 23;8:1168-76 [19030762.001]
  • [Cites] Cancer Cell. 2015 Dec 14;28(6):800-14 [26585400.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Development. 2012 Feb;139(3):465-74 [22190642.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12 ):1767-9 [17465465.001]
  • [Cites] Therap Adv Gastroenterol. 2011 Mar;4(2):89-94 [21694810.001]
  • [Cites] Dig Dis Sci. 2010 Nov;55(11):3124-31 [20668939.001]
  • [Cites] Oncogene. 2014 Dec 4;33(49):5637-48 [24317510.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Sep;3(9):1176-86 [20651033.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2337-40 [11513171.001]
  • [Cites] Int J Cancer. 2013 May 1;132(9):2192-9 [23034724.001]
  • [Cites] PLoS One. 2015 Jul 31;10(7):e0133403 [26230607.001]
  • [Cites] Cell Stem Cell. 2015 Jun 4;16(6):627-38 [26046762.001]
  • [Cites] Am J Anat. 1985 Mar;172(3):205-24 [3993597.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1188-93 [11688579.001]
  • [Cites] Dig Dis Sci. 2013 Mar;58(3):634-40 [23053898.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Aliment Pharmacol Ther. 2015 Sep;42(6):649-63 [26177572.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1113-21 [11910361.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8 [18556417.001]
  • [Cites] N Engl J Med. 2014 Dec 25;371(26):2499-509 [25539106.001]
  • [Cites] Am J Surg Pathol. 2011 May;35(5):647-55 [21422910.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Sep;5(9):517-26 [18679388.001]
  • [Cites] Nat Genet. 2014 Jun;46(6):583-7 [24816255.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):92-105 [12105837.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1889-94 [8467510.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):353-60 [10365894.001]
  • [Cites] Cell Stem Cell. 2010 Jan 8;6(1):25-36 [20085740.001]
  • [Cites] Cancer Prev Res (Phila). 2014 Jan;7(1):114-27 [24253313.001]
  • [Cites] Gastroenterology. 2015 Feb;148(2):367-78 [25447851.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Helicobacter. 1999 Dec;4(4):281-3 [10597399.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2354-66 [15735748.001]
  • [Cites] Am J Gastroenterol. 2000 Jun;95(6):1431-8 [10894575.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] Crit Rev Oncol Hematol. 2014 Oct;92(1):25-37 [24935219.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Cancer Cell. 2012 Jan 17;21(1):36-51 [22264787.001]
  • [Cites] Gut. 2004 Oct;53(10 ):1416-23 [15361487.001]
  • [Cites] Regul Pept. 2001 Dec 15;102(2-3):101-10 [11730982.001]
  • [Cites] Gastroenterology. 2010 Dec;139(6):2028-2037.e9 [20854822.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Nat Commun. 2014 Dec 11;5:5728 [25500896.001]
  • [Cites] Nat Genet. 2014 Aug;46(8):837-43 [24952744.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Development. 2010 Dec;137(24):4171-6 [21068065.001]
  • [Cites] Dig Dis Sci. 2007 Nov;52(11):3054-65 [17394068.001]
  • [Cites] Gastroenterology. 2013 Oct;145(4):730-9 [23796455.001]
  • [Cites] Gut. 2007 Nov;56(11):1503-11 [17337464.001]
  • [Cites] J Biol Chem. 2014 Nov 28;289(48):33343-54 [25320087.001]
  • [Cites] Clin Gastroenterol Hepatol. 2015 Dec;13(13):2241-55.e1-4; quiz e179 [26188139.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):747-9 [10328099.001]
  • [Cites] J Vis Exp. 2015 Aug 25;(102):e53012 [26327430.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] J Natl Cancer Inst. 2014 Sep 30;106(11):null [25269698.001]
  • [Cites] Am J Epidemiol. 2011 Feb 1;173(3):259-70 [21178102.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] Nat Med. 2015 May;21(5):449-56 [25894828.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Development. 2007 Jul;134(13):2521-31 [17522155.001]
  • [Cites] Gastrointest Cancer Res. 2009 Mar;3(2 Suppl):S2-5 [19461918.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Am J Gastroenterol. 1997 Dec;92(12):2220-4 [9399757.001]
  • [Cites] Gut. 2012 May;61(5):673-84 [22315472.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):500-10 [18242216.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • [Cites] Gastroenterol Clin North Am. 2015 Jun;44(2):473-89 [26021206.001]
  • [Cites] Gut. 2016 Jun;65(6):907-13 [26701877.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):408-19 [18977329.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1701-6 [16551852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4251-6 [22375031.001]
  • [Cites] World J Gastroenterol. 2009 Nov 21;15(43):5465-71 [19916178.001]
  • [Cites] J Gastrointest Oncol. 2012 Sep;3(3):251-61 [22943016.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Nat Cell Biol. 2015 Aug;17(8):984-93 [26192439.001]
  • [Cites] N Engl J Med. 1976 Aug 26;295(9):476-80 [940579.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Jan 10;109 (2):466-71 [22190486.001]
  • [Cites] Gastroenterology. 2013 May;144(5):956-966.e4 [23333711.001]
  • [Cites] Jpn J Clin Oncol. 2014 Sep;44(9):783-91 [24951830.001]
  • [Cites] Gastroenterology. 2011 Mar;140(3):879-91 [21111741.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1915-9 [15026323.001]
  • [Cites] Cell Stem Cell. 2011 Oct 4;9(4):317-29 [21982232.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2012 Sep 1;72(17):4383-93 [22751462.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):188-95 [3947155.001]
  • (PMID = 27112208.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Tam V, Luketich JD, Winger DG, Sarkaria IS, Levy RM, Christie NA, Awais O, Shende MR, Nason KS: Cancer Recurrence After Esophagectomy: Impact of Postoperative Infection in Propensity-Matched Cohorts. Ann Thorac Surg; 2016 Nov;102(5):1638-1646
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Postoperative infection increases cancer recurrence and worsens survival in colorectal cancer, but the relationship for esophagogastric adenocarcinoma after esophagectomy is not well defined.
  • We aimed to determine whether recurrence and survival after minimally invasive esophagectomy for esophagogastric adenocarcinoma were influenced by postoperative infection using propensity-matched analysis.
  • METHODS: We abstracted data for 810 patients (1997-2010) and defined exposure as at least 1 in-hospital or 30-day infectious complication (n = 206 [25%]).
  • CONCLUSIONS: In patients with esophagogastric adenocarcinoma, infections after esophagectomy were not associated with an increased rate or earlier time to recurrence when baseline characteristics associated with infection risk were balanced using propensity-score matching.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Neoplasm Recurrence, Local / etiology. Neoplasm Staging. Surgical Wound Infection / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [Cites] Ann Surg. 2011 May;253(5):890-9 [21394013.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):215-9 [12555298.001]
  • [Cites] PLoS One. 2015 Dec 30;10(12):e0143080 [26717416.001]
  • [Cites] Oncol Rep. 2006 Apr;15(4):895-901 [16525677.001]
  • [Cites] Ann Surg. 2009 Nov;250(5):798-807 [19809297.001]
  • [Cites] Ann Surg. 2015 Dec;262(6):972-80 [26469952.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1150-4 [16035134.001]
  • [Cites] Ann Surg. 2015 Mar;261(3):497-505 [25185465.001]
  • [Cites] Onco Targets Ther. 2014 Sep 30;7:1811-5 [25336972.001]
  • [Cites] Surg Today. 2012 Jan;42(2):141-6 [22094435.001]
  • [Cites] Cancer Lett. 2014 Apr 10;345(2):182-9 [23994342.001]
  • [Cites] World J Surg. 2000 Jan;24(1):10-6 [10594196.001]
  • [Cites] Oncotarget. 2016 Mar 29;7(13):15525-38 [26771842.001]
  • [Cites] Br J Surg. 2013 Jan;100(1):95-104 [23148025.001]
  • [Cites] J Gastrointest Surg. 2010 Oct;14(10):1492-501 [20824375.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):71-6 [18156925.001]
  • [Cites] Am J Cancer Res. 2015 Jun 15;5(7):2180-9 [26328248.001]
  • [Cites] Tumour Biol. 2016 Mar;37(3):3081-90 [26423404.001]
  • [Cites] World J Surg. 2011 Aug;35(8):1861-6 [21538187.001]
  • [Cites] Clin Cancer Res. 2010 Dec 1;16(23):5824-34 [20947516.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] World J Surg. 2015 Jan;39(1):216-22 [25189448.001]
  • [Cites] J Thorac Cardiovasc Surg. 2015 Jul;150(1):14-9 [25963441.001]
  • [Cites] Surgery. 2010 Oct;148(4):831-8; discussion 838-40 [20800864.001]
  • [Cites] Eur J Surg Oncol. 2015 Oct;41(10):1308-15 [26235238.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393-403 [25106775.001]
  • [Cites] Surg Today. 2013 Jan;43(1):48-54 [23001546.001]
  • [Cites] Dis Colon Rectum. 2009 Mar;52(3):380-6 [19333035.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G571-81 [20299604.001]
  • [Cites] Cancer Sci. 2014 Sep;105(9):1205-11 [25040886.001]
  • (PMID = 27353482.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA151613; United States / NCI NIH HHS / CA / L30 CA179766; United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Mokrowiecka A, Zonnur S, Veits L, Musial J, Kordek R, Lochowski M, Kozak J, Malecka-Panas E, Vieth M, Hartmann A: Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis. Dig Dis Sci; 2013 Mar;58(3):699-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.
  • Liver-intestine (LI)-cadherin, an intestine-specific marker, is involved in intestinal metaplasia development in gastric and colon cancers and could be of value in diagnosis and differentiation.
  • METHODS: LI-cadherin expression was immunohistologically investigated, by use of anti-CDH17 antibody, in gastric mucosa (GM) biopsies taken from the cardia (n = 9), in Barrett's esophagus (BE) without intraepithelial neoplasia (without IEN) (n = 9) and BE with low-grade IEN (n = 11), and in esophageal adenocarcinoma (ADC) (n = 13).
  • RESULTS: The immunoreactivity score was highest in adenocarcinoma (mean IRS = 4.0), and dropped gradually from BE with IEN and BE without IEN (mean IRS = 2.0) to cardia mucosa (IRS = 0).
  • CONCLUSIONS: LI-cadherin is a sensitive marker of intestinal metaplasia and can be helpful for early histologic diagnosis of Barrett's esophagus; it is, however, not significantly different between BE with and without IEN, and cannot be used to distinguish between these.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Cardia / metabolism. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000;915:136-43 [11193569.001]
  • [Cites] Gut. 2001 Jul;49(1):73-81 [11413113.001]
  • [Cites] Biochim Biophys Acta. 2001 Nov 30;1552(1):39-45 [11781114.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1565-77 [12404231.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] J Gastroenterol. 2003;38(1):14-22 [12560917.001]
  • [Cites] Cancer Sci. 2003 May;94(5):425-30 [12824888.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):618-24 [14623315.001]
  • [Cites] Acta Biochim Pol. 2004;51(2):445-57 [15218541.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1353-69 [8207063.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):740-6 [7833053.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Curr Opin Cell Biol. 1997 Feb;9(1):76-85 [9013677.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Dec;26(3):163-73 [9481522.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Biochem Cell Biol. 1998;76(6):957-69 [10392709.001]
  • [Cites] J Pathol. 2005 Apr;205(5):615-22 [15732140.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):536-42 [17226075.001]
  • [Cites] Histopathology. 2007 Jun;50(7):920-7 [17543082.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Dig Dis Sci. 2008 Jul;53(7):1811-7 [17999183.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8 [18556417.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):65-74 [18755496.001]
  • [Cites] Am J Gastroenterol. 2009 Apr;104(4):816-24 [19293780.001]
  • [Cites] Int J Oncol. 2010 Jan;36(1):245-54 [19956853.001]
  • [Cites] Digestion. 2009;80(4):248-57 [19828957.001]
  • [Cites] Biochem Soc Trans. 2010 Apr;38(2):364-9 [20298184.001]
  • [Cites] Virchows Arch. 2010 Nov;457(5):537-45 [20844891.001]
  • [Cites] Int J Surg Pathol. 2010 Oct;18(5):330-7 [20444732.001]
  • (PMID = 23053896.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH17 protein, human; 0 / Cadherins
  • [Other-IDs] NLM/ PMC3616226
  •  go-up   go-down


6. Chen F, Ren P, Feng Y, Liu H, Sun Y, Liu Z, Ge J, Cui X: Follistatin is a novel biomarker for lung adenocarcinoma in humans. PLoS One; 2014;9(10):e111398
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follistatin is a novel biomarker for lung adenocarcinoma in humans.
  • However, whether FST can serve as a biomarker for diagnosis in lung adenocarcinoma of humans remains unclear.
  • METHODS AND RESULTS: The study population consisted of 80 patients with lung adenocarcinoma, 40 patients with ovarian adenocarcinoma and 80 healthy subjects.
  • The results showed that the positive ratio of serum FST levels was 51.3% (41/80), which was comparable to the sensitivity of FST in 40 patients with ovarian adenocarcinoma (60%, 24/40) using the 95th confidence interval for the healthy subject group as the cut-off value.
  • FST expressions in lung adenocarcinoma were examined by immunohistochemical staining, we found that lung adenocarcinoma could produce FST and there was positive correlation between the level of FST expression and the differential degree of lung adenocarcinoma.
  • Furthermore, the results showed that primary cultured lung adenocarcinoma cells could secrete FST, while cells derived from non-tumor lung tissues almost did not produce FST.
  • In addition, the results of CCK8 assay and flow cytometry showed that using anti-FST monoclonal antibody to neutralize endogenous FST significantly augmented activin A-induced lung adenocarcinoma cells apoptosis.
  • CONCLUSIONS: These data indicate that lung adenocarcinoma cells can secret FST into serum, which may be beneficial to the survival of adenocarcinoma cells by neutralizing activin A action.
  • Thus, FST can serve as a promising biomarker for diagnosis of lung adenocarcinoma and a useful biotherapy target for lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Follistatin / blood. Lung Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2001 Jun 30;180(1-2):179-82 [11451589.001]
  • [Cites] Target Oncol. 2013 Dec;8(4):215-23 [23456439.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Dec 16;149(2):744-9 [3122741.001]
  • [Cites] Biochim Biophys Acta. 1992 Apr 30;1135(1):103-9 [1591267.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):705-10 [1325994.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Dec 15;197(2):985-91 [8267637.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):630-4 [8636280.001]
  • [Cites] Mol Cell Endocrinol. 1996 Jan 15;116(1):105-14 [8822271.001]
  • [Cites] Endocr J. 1996 Jun;43(3):321-7 [8886627.001]
  • [Cites] Biol Reprod. 1997 Nov;57(5):1211-6 [9369189.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):535-43 [16198295.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G137-44 [16123203.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2842-9 [17103443.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):660-7 [18245525.001]
  • [Cites] Oncol Rep. 2009 Feb;21(2):491-7 [19148527.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Apr 3;381(2):229-35 [19338778.001]
  • [Cites] Toxicology. 2009 Apr 28;258(2-3):176-83 [19428937.001]
  • [Cites] Chest. 2009 Jul;136(1):260-71 [19584208.001]
  • [Cites] Cell Mol Immunol. 2009 Oct;6(5):387-92 [19887052.001]
  • [Cites] Biol Reprod. 2009 Dec;81(6):1139-46 [19641179.001]
  • [Cites] Mol Cell Proteomics. 2009 Dec;8(12):2746-58 [19776420.001]
  • [Cites] Reprod Sci. 2010 Apr;17(4):320-30 [20228378.001]
  • [Cites] Clin Exp Metastasis. 2010 Dec;27(8):549-55 [20623366.001]
  • [Cites] J Biol Chem. 2010 Nov 19;285(47):36857-64 [20843798.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2893-917 [21351269.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2918-27 [21351270.001]
  • [Cites] Br J Cancer. 2011 Jul 26;105(3):382-92 [21750552.001]
  • [Cites] Cancer. 2011 Oct 1;117(19):4381-9 [21412758.001]
  • [Cites] Biol Trace Elem Res. 2011 Dec;144(1-3):306-15 [21625915.001]
  • [Cites] Immunol Cell Biol. 2012 Feb;90(2):137-48 [21537340.001]
  • [Cites] J Int Med Res. 2012;40(3):877-86 [22906260.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2012 Oct;56(7):461-4 [23108752.001]
  • [Cites] Lung Cancer. 2013 Apr;80(1):45-9 [23352032.001]
  • [Cites] Biochem Biophys Res Commun. 2013 May 31;435(2):222-8 [23665022.001]
  • [Cites] Asian Pac J Cancer Prev. 2013;14(7):4369-71 [23992005.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):110-20 [12531697.001]
  • (PMID = 25347573.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Follistatin
  • [Other-IDs] NLM/ PMC4210220
  •  go-up   go-down


7. Sugimoto K, Kawai M, Takehara K, Tashiro Y, Munakata S, Ishiyama S, Komiyama H, Takahashi M, Kojima Y, Goto M, Tomiki Y, Sakamoto K, Kawasaki S: T1 colorectal cancer with synchronous liver metastasis. Case Rep Gastroenterol; 2013 May;7(2):266-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T1 colorectal cancer with synchronous liver metastasis.
  • The patient was a 68-year-old man who was admitted to our hospital with a liver tumor.
  • Abdominal ultrasonography and computed tomography revealed a liver tumor 30 mm in diameter.
  • On histopathological examination of the resected specimen, the tumor was a well-differentiated tubular adenocarcinoma with 3,000 μm invasion of the submucosal layer.
  • The liver tumor showed histological findings similar to those of the primary colorectal carcinoma.
  • Nine months after the operation, computed tomography revealed hepatic hilar lymph node metastases and a great deal of ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23898232.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3724139
  • [Keywords] NOTNLM ; Distant metastasis / Lymph node metastasis / Risk factor / Synchronous liver metastasis / T1 colorectal cancer
  •  go-up   go-down


8. Tettey M, Edwin F, Aniteye E, Sereboe L, Tamatey M, Ofosu-Appiah E, Adzamli I: The changing epidemiology of esophageal cancer in sub-Saharan Africa - the case of Ghana. Pan Afr Med J; 2012;13:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to evaluate the current national trend in the presentation and outcome of esophageal cancer using our institutional experience from 1992 - 2010.
  • The yearly trend from 1992 to 2010 showed a steady increase in the incidence of esophageal cancer.
  • Squamous cell carcinoma accounted for 78.7% and adenocarcinoma 21.3%.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):S1367-9 [14530066.001]
  • [Cites] Am J Epidemiol. 2001 Jan 15;153(2):114-22 [11159155.001]
  • [Cites] J Surg Oncol. 1973;5(3):267-75 [4712292.001]
  • [Cites] Cancer Res. 1978 Feb;38(2):303-7 [620403.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Natl Med Assoc. 2005 Nov;97(11):1471-8 [16334494.001]
  • [Cites] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Jun;151(1):17-20 [17690734.001]
  • [Cites] J Gastrointestin Liver Dis. 2007 Sep;16(3):245-9 [17925916.001]
  • [Cites] BMJ. 2010;341:c6280 [21112905.001]
  • [Cites] PLoS One. 2010;5(11):e14080 [21124934.001]
  • [Cites] Scand J Gastroenterol. 2011 May;46(5):597-602 [21271900.001]
  • [Cites] Indian J Cancer. 2011 Apr-Jun;48(2):165-9 [21768660.001]
  • [Cites] J Natl Compr Canc Netw. 2011 Aug 1;9(8):830-87 [21900218.001]
  • [Cites] Malawi Med J. 2010 Sep;22(3):65-70 [21977849.001]
  • [Cites] Ann Thorac Surg. 1999 Oct;68(4):1133-6; discussion 1136-7 [10543468.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):980-7 [15181133.001]
  • (PMID = 23308313.001).
  • [ISSN] 1937-8688
  • [Journal-full-title] The Pan African medical journal
  • [ISO-abbreviation] Pan Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC3527059
  • [Keywords] NOTNLM ; Esophageal cancer / adenocarcinoma / dysphagia / squamous cell carcinoma
  •  go-up   go-down


9. Baghdadi J, Chaudhary N, Pei Z, Yang L: Microbiome, innate immunity, and esophageal adenocarcinoma. Clin Lab Med; 2014 Dec;34(4):721-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbiome, innate immunity, and esophageal adenocarcinoma.
  • The incidence of esophageal adenocarcinoma (EAC) has increased dramatically in the United States.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Dis Esophagus. 1998 Oct;11(4):248-50 [10071807.001]
  • [Cites] Mediators Inflamm. 2010;2010. pii: 581837. doi: 10.1155/2010/581837 [20871832.001]
  • [Cites] Am J Gastroenterol. 2013 Jul;108(7):1082-93 [23588239.001]
  • [Cites] Dis Esophagus. 2013 Jul;26(5):517-21 [22891654.001]
  • [Cites] Virchows Arch. 2014 Jan;464(1):11-8 [24221343.001]
  • [Cites] Gut Microbes. 2014 Jan-Feb;5(1):64-70 [24418972.001]
  • [Cites] J Gastroenterol. 2014 Jul;49(7):1121-34 [23955118.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3749-52 [10201887.001]
  • [Cites] J Microbiol. 2005 Feb;43 Spec No:93-100 [15765062.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1257-64 [15929754.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5 [16033867.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2299-306 [16181384.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7277-83 [16437628.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):952-7 [16467164.001]
  • [Cites] Scand J Gastroenterol. 2007 Mar;42(3):410-1 [17354124.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Arch Surg. 2007 Jun;142(6):554-9; discussion 559-60 [17576892.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1413-7, 1417.e1-2 [17997357.001]
  • [Cites] Cancer Sci. 2008 May;99(5):836-42 [18294278.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8 [18556417.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] J Clin Virol. 2008 Oct;43(2):250-2 [18718811.001]
  • [Cites] Mol Med. 2008 Sep-Oct;14(9-10):645-59 [18584047.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] J Clin Virol. 2009 May;45(1):28-33 [19307150.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):588-97 [19394334.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2009 Dec;297(6):G1172-80 [19779021.001]
  • [Cites] J Clin Pathol. 2010 Jan;63(1):1-3 [20026700.001]
  • [Cites] BMC Cancer. 2010;10:19 [20078887.001]
  • [Cites] FEMS Microbiol Rev. 2010 Jul;34(4):415-25 [20059548.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Jun;14(6):729-35 [10848656.001]
  • [Cites] Digestion. 2000;62(2-3):95-9 [11025356.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G32-42 [11123195.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):349S-355S [11189687.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2395-8 [11289103.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1099-103 [11323673.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Nov;32(10):1222-7 [20955441.001]
  • [Cites] World J Gastroenterol. 2010 Dec 14;16(46):5901-6 [21155014.001]
  • [Cites] J Clin Virol. 2011 Mar;50(3):205-8 [21169053.001]
  • [Cites] Histopathology. 2011 Oct;59(4):643-9 [22014045.001]
  • [Cites] JAMA. 2012 Feb 15;307(7):693-703 [22282321.001]
  • [Cites] Dig Dis Sci. 2012 Mar;57(3):630-42 [21960283.001]
  • [Cites] BMC Infect Dis. 2013;13:130 [23496929.001]
  • [Cites] Mol Pharmacol. 2013 May;83(5):978-90 [23439561.001]
  • [Cites] Gut. 2002 Apr;50(4):451-9 [11889061.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2003 Mar;98(3):551-6 [12650786.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Dis Esophagus. 2000;13(2):122-4 [14601902.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4250-5 [15016918.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):589-97 [15089887.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1319-23 [15154668.001]
  • [Cites] Scand J Gastroenterol. 2004 Sep;39(9):816-22 [15513378.001]
  • [Cites] Thorax. 1982 Mar;37(3):181-4 [7101222.001]
  • [Cites] Ann R Coll Surg Engl. 1983 May;65(3):152-4 [6859774.001]
  • [Cites] Gastroenterology. 1985 Oct;89(4):797-804 [4029559.001]
  • [Cites] J Bacteriol. 1991 Jan;173(2):697-703 [1987160.001]
  • [Cites] Ann Fr Anesth Reanim. 1994;13(5 Suppl):S161-8 [7778805.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):24-9 [9066743.001]
  • (PMID = 25439272.001).
  • [ISSN] 1557-9832
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA159036; United States / NCI NIH HHS / CA / U01CA18237; United States / NCI NIH HHS / CA / UH3 CA140233; United States / NIEHS NIH HHS / ES / R21ES023421; United States / NIEHS NIH HHS / ES / R21 ES023421; United States / NCI NIH HHS / CA / R03CA159414; United States / NCI NIH HHS / CA / R03 CA159414; United States / NIAID NIH HHS / AI / R01 AI110372; United States / NCI NIH HHS / CA / U01 CA182370; United States / NCI NIH HHS / CA / R01CA159036; United States / NCI NIH HHS / CA / UH3CA140233; United States / NIAID NIH HHS / AI / R01AI110372
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  • [Other-IDs] NLM/ NIHMS625731; NLM/ PMC4254553
  • [Keywords] NOTNLM ; Adenocarcinoma / Bacteria / Barrett esophagus / Chronic inflammation / Innate immunity / Microbiome / Reflux / Viruses
  •  go-up   go-down






Advertisement